SpringerLink
Log in

Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstracts

Purposes

To gain a better understanding of the overall incidence and risk of hypertension in cancer patients who receive pazopanib and to compare the differences in incidence among sorafenib, sunitinib, and pazopanib.

Methods

Several databases were searched, including PubMed, Embase, and Cochrane databases. Eligible studies were phase II and III prospective clinical trials of patients with cancer assigned single drug pazopanib 800 mg/day with data on hypertension available. Overall incidence rates, relative risk (RR), and 95 % confidence intervals (CI) were calculated employing fixed or random effects models depending on the heterogeneity of the included trials.

Results

A total of 1,651 patients with a variety of solid tumors from 13 clinical trials were included for the meta-analysis. The overall incidences of all-grade and high-grade hypertension in cancer patients were 35.9 % (95 % CI 31.5–40.6 %) and 6.5 % (95 % CI 5.2–8.0 %), respectively. The use of pazopanib was associated with an increased risk of develo** all-grade (RR 4.97, 95 % CI 3.38–7.30, p < 0.001) and high-grade hypertension (RR 2.87, 95 % CI 1.16–7.12, p = 0.023). Additionally, there was no significant difference in the incidence of all-grade (RR 1.21, 95 % CI 0.96–1.53, p = 0.11) and high-grade hypertension (RR 1.29, 95 % CI 0.80–2.07, p = 0.30) between RCC and non-RCC patients. Interestingly, the risk of all-grade hypertension with pazopanib was substantially higher than sorafenib (RR 1.99; 95 % CI 1.73–2.29, p = 0.00) and sunitinib (RR 2.20; 95 % CI 1.92–2.52, p = 0.00), while the risk of pazopanib-induced high-grade hypertension was similar to sorafenib (RR 0.98; 95 % CI 0.75–1.30, p = 0.90) and sunitinib (RR 0.81; 95 % CI 0.62–1.06, p = 0.12).

Conclusions

The use of pazopanib is associated with a significantly increased risk of develo** hypertension. Close monitoring and appropriate managements are recommended during the therapy. Future studies are still needed to investigate the risk reduction and possible use of pazopanib in selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72(8):1909–1914

    Article  PubMed  CAS  Google Scholar 

  2. Tie J, Desai J (2012) Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog 17(1):51–67

    Article  PubMed  Google Scholar 

  3. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400

    Article  PubMed  CAS  Google Scholar 

  4. US Food and Drug Administration. Highlights of Prescribing Information. Votrient (pazopanib) tablets. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf. Accessed 11 Jun 2012

  5. European Medicines Agency. CHMPassessment report Votrient. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001141/WC500094275.pdf. Accessed 11 Jun 2012

  6. Bukowski RM, Yasothan U, Kirkpatrick P (2010) Pazopanib. Nat Rev Drug Discov 9(1):17–18

    Article  PubMed  CAS  Google Scholar 

  7. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068

    Article  PubMed  CAS  Google Scholar 

  8. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879–1886

    Article  PubMed  Google Scholar 

  9. National Cancer Institute: Clinical trial search results. http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=10710684 Accessed 11 Jun 2012

  10. van Geel RM, Beijnen JH, Schellens JH (2012) Concise drug review: pazopanib and axitinib. Oncologist 17:1081–1089

    Google Scholar 

  11. Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A et al (2012) An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Eur J Cancer 48:3171–3176

    Google Scholar 

  12. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM et al (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12(24):7271–7278

    Article  PubMed  CAS  Google Scholar 

  13. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505–2512

    Article  PubMed  CAS  Google Scholar 

  14. Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A et al (2010) Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 46(13):2432–2440

    Article  PubMed  CAS  Google Scholar 

  15. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A et al (2011) Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 104(5):741–745

    Article  PubMed  CAS  Google Scholar 

  16. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117–123

    Article  PubMed  CAS  Google Scholar 

  17. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48(1):9–17

    Article  PubMed  CAS  Google Scholar 

  18. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC et al (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7):2012–2021

    Article  PubMed  CAS  Google Scholar 

  19. Taylor SK, Chia S, Dent S, Clemons M, Agulnik M, Grenci P et al (2010) A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 15(8):810–818

    Article  PubMed  CAS  Google Scholar 

  20. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME et al (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11(10):962–972

    Article  PubMed  CAS  Google Scholar 

  21. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139(11):901–906

    PubMed  Google Scholar 

  22. NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

  23. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28(13):2280–2285

    Article  PubMed  CAS  Google Scholar 

  24. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28(2):123–137

    Article  PubMed  Google Scholar 

  25. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27(5):335–371

    Article  PubMed  CAS  Google Scholar 

  26. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101

    Article  PubMed  CAS  Google Scholar 

  27. Hutson TE, Davis ID, Machiels JPH, De Souza PL, Rottey S (2009) Hong Bf, et al. Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 28(3):475–480

    Article  PubMed  Google Scholar 

  28. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27(19):3126–3132

    Article  PubMed  CAS  Google Scholar 

  29. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H et al (2010) Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 28(19):3131–3137

    Article  PubMed  CAS  Google Scholar 

  30. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM et al (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119(1):32–37

    Article  PubMed  CAS  Google Scholar 

  31. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA et al (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06–02). Neuro Oncol 12(8):855–861

    Article  PubMed  CAS  Google Scholar 

  32. Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W et al (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 8(22):3562–3569

    Article  Google Scholar 

  33. Lim WT, Ng QS, Ivy P, Leong SS, Singh O, Chowbay B et al (2011) A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res 17(16):5481–5489

    Article  PubMed  CAS  Google Scholar 

  34. Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ et al (2011) A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis 15(1):87–92

    Article  PubMed  Google Scholar 

  35. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F et al (2012) Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 13:810–816

    Google Scholar 

  36. An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB et al (2010) Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 66(8):813–821

    Article  PubMed  CAS  Google Scholar 

  37. Sica DA (2006) Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 24(9):1329–1331

    Article  PubMed  Google Scholar 

  38. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR et al (2006) Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol 24(9):1363–1369

    Article  PubMed  CAS  Google Scholar 

  39. Ravaud A, Sire M (2009) Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol 20(5):966–967 author reply 967

    Article  PubMed  CAS  Google Scholar 

  40. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123(10):754–762

    PubMed  CAS  Google Scholar 

  41. Siddiqui AJ, Mansson-Broberg A, Gustafsson T, Grinnemo KH, Dellgren G, Hao X et al (2005) Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens 18(10):1347–1352

    Article  PubMed  CAS  Google Scholar 

  42. Miura S, Fu**o M, Matsuo Y, Tanigawa H, Saku K (2005) Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 28(2):147–153

    Article  PubMed  CAS  Google Scholar 

  43. Grunwald V, Heinzer H, Fiedler W (2007) Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 30(10):519–524

    Article  PubMed  Google Scholar 

  44. Agabiti-Rosei E (2003) Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy. Drugs 63(1):19–29

    Article  PubMed  CAS  Google Scholar 

  45. Lane PW (2012) Meta-analysis of incidence of rare events. Stat Methods Med Res. doi:10.1177/0962280211432218

Download references

Acknowledgments

The study was supported by grants from the National Natural Science Foundation of China (81001191) and Science and Technology Commission of Shanghai (10PJ1408300).

Conflicts of interest

All authors declare that they have no potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Oncology, The Sixth People’s Hospital, Shanghai Jiao Tong University, No. 600, yishan road, Shanghai, 200233, China

    Wei-**ang Qi, Feng Lin, Yuan-jue Sun, Li-Na Tang, Ai-Na He, Yang Yao & Zan Shen

Authors
  1. Wei-**ang Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feng Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan-jue Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li-Na Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ai-Na He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yang Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zan Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yang Yao or Zan Shen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qi, WX., Lin, F., Sun, Yj. et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 71, 431–439 (2013). https://doi.org/10.1007/s00280-012-2025-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-2025-5

Keywords

Search

Navigation